Corcept Therapeutics (CORT)


Market Price (11/18/2026): $70.99 | Market Cap: $7.8 BilSector: Health Care | Industry: Pharmaceuticals

Corcept Therapeutics (CORT)


Market Price (11/18/2026): $70.99
Market Cap: $7.8 Bil
Sector: Health Care
Industry: Pharmaceuticals

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 21%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 20%

Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -30%

Megatrend and thematic drivers
Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.

Weak multi-year price returns
2Y Excs Rtn is -2.7%

Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 67x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 38x, P/EPrice/Earnings or Price/(Net Income) is 46x

Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 11%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -2.9%

Key risks
CORT key risks include [1] patent litigation threatening market exclusivity for its primary drug, Show more.

0 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 21%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 20%
1 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -30%
2 Megatrend and thematic drivers
Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.
3 Weak multi-year price returns
2Y Excs Rtn is -2.7%
4 Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 67x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 38x, P/EPrice/Earnings or Price/(Net Income) is 46x
5 Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 11%
6 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -2.9%
7 Key risks
CORT key risks include [1] patent litigation threatening market exclusivity for its primary drug, Show more.

CORT in ETFs

Weight = CORT's share of each fund

VTI0.01%
ITOT0.01%
IWB0.01%
IJH0.20%
VB0.10%
MDYG0.41%
IJK0.41%
VBK0.23%
+19 more covered ETFs

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Prices as of 11/17/2026

Nov 16: down 5.1% in one day (S&P 500 down 1.9%)
The stock declined as the broader market also moved lower, with chip and financial stocks dragging the market down. This occurred despite Corcept Therapeutics announcing a case report detailing an eight-year response to Relacorilant plus Nab-Paclitaxel.

Down 44.0% from its Aug 25 high to Nov 16 (S&P 500 down 3.1%)
The stock declined significantly over this period, with its largest daily drops occurring without specific company news. The biggest daily declines were Oct 23 and Oct 22, while Nov 5 also saw a sharp drop.

Nov 4: down 3.3% the day after its Nov 3 earnings report (S&P 500 up 1.7%)
The stock declined following its Q3 earnings report on Nov 4, which indicated beats on revenue and net income driven by strong product sales, as the broader market moved higher that day.

Show more
Prices as of 11/17/2026

Nov 16: down 5.1% in one day (S&P 500 down 1.9%)
The stock declined as the broader market also moved lower, with chip and financial stocks dragging the market down. This occurred despite Corcept Therapeutics announcing a case report detailing an eight-year response to Relacorilant plus Nab-Paclitaxel.

Down 44.0% from its Aug 25 high to Nov 16 (S&P 500 down 3.1%)
The stock declined significantly over this period, with its largest daily drops occurring without specific company news. The biggest daily declines were Oct 23 and Oct 22, while Nov 5 also saw a sharp drop.

Nov 4: down 3.3% the day after its Nov 3 earnings report (S&P 500 up 1.7%)
The stock declined following its Q3 earnings report on Nov 4, which indicated beats on revenue and net income driven by strong product sales, as the broader market moved higher that day.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The -38.8% change in CORT stock from 7/31/2026 to 11/17/2026 was primarily driven by a -78.9% change in the company's P/E Multiple.
(LTM values as of)731202611172026Change
Stock Price ($)114.4970.07-38.8%
Change Contribution By: 
Total Revenues ($ Mil)83196416.0%
Net Income Margin (%)6.6%16.8%153.6%
P/E Multiple218.646.0-78.9%
Shares Outstanding (Mil)105107-1.2%
Cumulative Contribution-38.8%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2026 to 11/17/2026
ReturnCorrelation
CORT-38.8% 
Market (SPY)-1.7%40.0%
Sector (XLV)14.4%23.4%

Fundamental Drivers

The 50.6% change in CORT stock from 4/30/2026 to 11/17/2026 was primarily driven by a 173.6% change in the company's Net Income Margin (%).
(LTM values as of)430202611172026Change
Stock Price ($)46.5270.0750.6%
Change Contribution By: 
Total Revenues ($ Mil)76996425.3%
Net Income Margin (%)6.2%16.8%173.6%
P/E Multiple102.646.0-55.1%
Shares Outstanding (Mil)104107-2.1%
Cumulative Contribution50.6%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 11/17/2026
ReturnCorrelation
CORT50.6% 
Market (SPY)2.4%34.2%
Sector (XLV)27.9%12.1%

Fundamental Drivers

The -4.6% change in CORT stock from 10/31/2025 to 11/17/2026 was primarily driven by a -19.6% change in the company's P/E Multiple.
(LTM values as of)1031202511172026Change
Stock Price ($)73.4770.07-4.6%
Change Contribution By: 
Total Revenues ($ Mil)71696434.6%
Net Income Margin (%)18.7%16.8%-9.8%
P/E Multiple57.246.0-19.6%
Shares Outstanding (Mil)104107-2.4%
Cumulative Contribution-4.6%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 11/17/2026
ReturnCorrelation
CORT-4.6% 
Market (SPY)8.5%31.6%
Sector (XLV)30.6%19.1%

Fundamental Drivers

The 149.5% change in CORT stock from 10/31/2023 to 11/17/2026 was primarily driven by a 125.1% change in the company's Total Revenues ($ Mil).
(LTM values as of)1031202311172026Change
Stock Price ($)28.0870.07149.5%
Change Contribution By: 
Total Revenues ($ Mil)428964125.1%
Net Income Margin (%)22.1%16.8%-23.8%
P/E Multiple30.346.052.1%
Shares Outstanding (Mil)102107-4.4%
Cumulative Contribution149.5%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2023 to 11/17/2026
ReturnCorrelation
CORT149.5% 
Market (SPY)81.6%23.8%
Sector (XLV)56.4%18.5%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
CORT Return-24%3%60%55%-31%101%168%
Peers Return-21%82%18%16%88%47%441%
S&P 500 Return27%-19%24%23%16%8%97%

Monthly Win Rates [3]
CORT Win Rate33%42%67%67%50%64% 
Peers Win Rate44%45%38%53%57%53% 
S&P 500 Win Rate75%42%67%75%67%36% 

Max Drawdowns [4]
CORT Max Drawdown-44%-33%-27%-35%-70%-44% 
Peers Max Drawdown-55%-46%-55%-55%-33%-32% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: XERS, MDGL, VKTX, BIIB, AMLX. See CORT Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/17/2026 (YTD)

How Low Can It Go

EventCORTS&P 500
2025 US Tariff Shock
  % Loss-26.2%-18.8%
  % Gain to Breakeven35.4%23.1%
  Time to Breakeven25 days79 days
2023 SVB Regional Banking Crisis
  % Loss-16.7%-6.7%
  % Gain to Breakeven20.1%7.1%
  Time to Breakeven61 days31 days
2022 Inflation Shock & Fed Tightening
  % Loss-18.7%-24.5%
  % Gain to Breakeven23.0%32.4%
  Time to Breakeven20 days427 days
2020 COVID-19 Crash
  % Loss-27.0%-33.7%
  % Gain to Breakeven36.9%50.9%
  Time to Breakeven60 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-22.2%-19.2%
  % Gain to Breakeven28.5%23.8%
  Time to Breakeven48 days105 days
2015-2016 China Devaluation / Global Growth Scare
  % Loss-40.1%-12.2%
  % Gain to Breakeven67.1%13.9%
  Time to Breakeven117 days62 days

Compare to XERS, MDGL, VKTX, BIIB, AMLX

In The Past

Corcept Therapeutics's stock fell -26.2% during the 2025 US Tariff Shock. Such a loss loss requires a 35.4% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventCORTS&P 500
2025 US Tariff Shock
  % Loss-26.2%-18.8%
  % Gain to Breakeven35.4%23.1%
  Time to Breakeven25 days79 days
2020 COVID-19 Crash
  % Loss-27.0%-33.7%
  % Gain to Breakeven36.9%50.9%
  Time to Breakeven60 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-22.2%-19.2%
  % Gain to Breakeven28.5%23.8%
  Time to Breakeven48 days105 days
2015-2016 China Devaluation / Global Growth Scare
  % Loss-40.1%-12.2%
  % Gain to Breakeven67.1%13.9%
  Time to Breakeven117 days62 days
2011 US Debt Ceiling Crisis & European Contagion
  % Loss-33.9%-17.9%
  % Gain to Breakeven51.4%21.8%
  Time to Breakeven152 days123 days
2008-2009 Global Financial Crisis
  % Loss-75.8%-53.4%
  % Gain to Breakeven313.3%114.4%
  Time to Breakeven343 days1085 days
Summer 2007 Credit Crunch
  % Loss-21.5%-8.6%
  % Gain to Breakeven27.5%9.5%
  Time to Breakeven7 days47 days

Compare to XERS, MDGL, VKTX, BIIB, AMLX

In The Past

Corcept Therapeutics's stock fell -26.2% during the 2025 US Tariff Shock. Such a loss loss requires a 35.4% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Corcept Therapeutics (CORT)

Corcept Therapeutics (CORT) is a biotechnology company dedicated to discovering, developing, and commercializing innovative drugs within the United States. The company's primary focus is on addressing severe metabolic, oncologic, and neuropsychiatric disorders, with a core emphasis on conditions stemming from cortisol excess or imbalance.

The cornerstone of Corcept's commercial operations is Korlym (mifepristone), an oral medication approved for adult patients with endogenous Cushing's syndrome. Korlym specifically treats hyperglycemia, a common symptom of hypercortisolism, in patients who also have type 2 diabetes mellitus or glucose intolerance and for whom surgery is not an option or has failed. This establishes Corcept's current market in a specialized endocrine disorder.

Looking to the future, Corcept possesses a strong pipeline of drug candidates, primarily selective cortisol modulators, to expand its therapeutic reach. Key developmental assets include relacorilant, intended to treat Cushing's syndrome, and a combination of nab-paclitaxel with relacorilant, which has shown promise in Phase II trials for advanced ovarian tumors and other forms of cortisol excess. The company is also exploring selective cortisol modulators for metastatic castration-resistant prostate cancer and for mitigating antipsychotic-induced weight gain, signaling potential entry into broader oncology and neuropsychiatric markets.

AI Analysis | Feedback

A rare disease drug developer, similar to Vertex Pharmaceuticals, but specializing in conditions caused by excess cortisol.

A specialized pharmaceutical company, akin to how Jazz Pharmaceuticals targets specific unmet needs in areas like narcolepsy and oncology, but focused on disorders related to cortisol modulation.

AI Analysis | Feedback

  • Korlym (mifepristone): An oral medication for adult patients with endogenous Cushing's syndrome to treat hyperglycemia secondary to hypercortisolism.
  • Relacorilant: A drug in development primarily for treating patients with Cushing's syndrome.
  • Nab-paclitaxel in combination with relacorilant: A therapeutic combination under development for advanced ovarian tumors and cortisol excess.
  • Selective cortisol modulator (for metastatic castration-resistant prostate cancer): A selective cortisol modulator in development to treat metastatic castration-resistant prostate cancer.
  • Selective cortisol modulator (for antipsychotic-induced weight gain and other disorders): A selective cortisol modulator in development for antipsychotic-induced weight gain and other disorders.
  • FKBP5 gene expression assays: Diagnostic or research tools for analyzing FKBP5 gene expression.

AI Analysis | Feedback

Corcept Therapeutics (CORT) is a pharmaceutical company that develops and commercializes prescription drugs. As such, it primarily sells its products to other companies within the healthcare supply chain, rather than directly to individual patients.

The major customers for pharmaceutical companies like Corcept are typically large drug wholesale distributors, who then distribute the medications to pharmacies, hospitals, and other healthcare providers. Based on industry standards, the major customers for Corcept Therapeutics are likely:

  • McKesson Corporation (MCK)
  • AmerisourceBergen Corporation (ABC)
  • Cardinal Health, Inc. (CAH)

AI Analysis | Feedback

null

AI Analysis | Feedback

Joseph K. Belanoff, M.D., Chief Executive Officer and President

Dr. Belanoff is a co-founder of Corcept Therapeutics, which was established in May 1998. He has served as the company's Chief Executive Officer since 1999 and as President since 2014. He has been an Adjunct Professor of Psychiatry at Stanford University since 1992. Dr. Belanoff holds a B.A. from Amherst College and an M.D. from Columbia University's College of Physicians & Surgeons. He has been instrumental in guiding Corcept from a research-focused entity to a commercial biopharmaceutical company with the approval of Korlym.

Atabak Mokari, Chief Financial Officer and Treasurer

Mr. Mokari joined Corcept Therapeutics as Chief Financial Officer in March 2021. He brings nearly 20 years of leadership experience in life sciences and healthcare finance. Before joining Corcept, he served as Chief Financial Officer and Vice President of Corporate Development at Bellicum Pharmaceuticals, Inc. from 2018 to 2020. From 2016 to 2018, he held the same role at medical device manufacturer IRIDEX Corporation. Mr. Mokari also worked as a director in healthcare investment banking at Wells Fargo Securities LLC (2013-2016), UBS (2009-2013), and Credit Suisse (2005-2009).

Charles Robb, Chief Business Officer and Secretary

Mr. Robb has served as Corcept's Chief Business Officer since March 2021, and as Secretary since January 2014. Prior to this, he was the company's Chief Financial Officer from September 2011 to March 2021. He possesses over 30 years of experience in executive management, operations, and finance. His past roles include Senior Vice President of Operations, Administration and Finance at Fitness Anywhere, Inc. He also founded a division at Citadon, Inc., focusing on workflow and analytic software for real estate lenders from 2000 to 2002. Mr. Robb practiced law from 1992 to 1996. He earned a B.A. from Yale University and a J.D. from Harvard Law School.

William Guyer, Pharm.D., Chief Development Officer

Dr. Guyer oversees Corcept Therapeutics' development pipeline, which includes the promising relacorilant program.

Hazel Hunt, Ph.D., Chief Scientific Officer

Dr. Hunt leads the discovery efforts for new selective cortisol modulators at Corcept Therapeutics.

AI Analysis | Feedback

Corcept Therapeutics (CORT) faces several key risks to its business:
  • Regulatory Setback and Litigation for Relacorilant: The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for relacorilant, Corcept's drug candidate for hypercortisolism, citing the need for additional evidence of effectiveness. This decision followed FDA concerns about the adequacy of the clinical development program, potential overestimation of efficacy in one trial, and safety concerns including drug-induced liver injury. This regulatory setback led to a significant decline in Corcept's stock price and has resulted in multiple shareholder class-action lawsuits alleging that the company misrepresented FDA communications and the likelihood of approval for relacorilant. The company will likely need to generate new clinical data to address the FDA's concerns.
  • Patent Litigation and Generic Competition for Korlym: Corcept's current primary revenue-generating product, Korlym, is protected by patents with expiration dates ranging from 2028 to 2037. However, Korlym has been the subject of ongoing patent litigations, with companies like Teva Pharmaceuticals and Neptune Generics LLC challenging the validity of these patents. Successful challenges could lead to an earlier-than-expected entry of generic versions of Korlym, which would significantly impact Corcept's revenue and market share.
  • Dependence on a Concentrated Product Portfolio: With Korlym as its main commercial product and relacorilant facing significant regulatory delays, Corcept Therapeutics remains highly dependent on a concentrated product portfolio. The setback for relacorilant, which was expected to be a key driver for future growth and diversification, highlights the risk associated with relying heavily on a limited number of drugs. Any adverse developments related to Korlym, such as increased competition or safety concerns, could have a disproportionately large impact on the company's financial performance.

AI Analysis | Feedback

null

AI Analysis | Feedback

Here's the information on the addressable markets for Corcept Therapeutics' main products:

  • Korlym (mifepristone) for Cushing's syndrome and relacorilant for Cushing's syndrome: The Cushing's disease market in the seven major markets (7MM: United States, EU4, UK, and Japan) was approximately USD 1,089 million in 2025. In 2024, the United States accounted for nearly USD 930 million of this market.
  • Nab-paclitaxel in combination with relacorilant for advanced ovarian tumors: The global advanced recurrent ovarian cancer market was valued at USD 3.70 billion in 2023 and is projected to reach USD 5.79 billion by the end of 2030.
  • Selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer: The total metastatic castration-resistant prostate cancer (mCRPC) market size across the seven major markets (7MM) was estimated at nearly USD 7,275.4 million in 2024. The United States market alone was approximately USD 4.4 billion in 2023.
  • Selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders: null

AI Analysis | Feedback

Corcept Therapeutics (CORT) is poised for future revenue growth over the next 2-3 years, driven by several key factors pertaining to its existing and pipeline products. Here are the expected drivers of future revenue growth for Corcept Therapeutics:
  1. Continued Growth of Korlym Sales: The company's sole marketed drug, Korlym, for Cushing's syndrome, is expected to continue its growth trajectory. Corcept anticipates sustained demand and has enhanced its specialty pharmacy capacity to meet this demand. For example, 2025 revenue from Korlym was $761 million, an increase from the prior year. Management forecasts a 2026 revenue guidance of $900 million to $1 billion, largely attributed to the Cushing's syndrome business.
  2. Launch and Commercialization of Relacorilant for Platinum-Resistant Ovarian Cancer: A significant near-term revenue driver is the anticipated approval and launch of relacorilant in combination with nab-paclitaxel for patients with platinum-resistant ovarian cancer. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of July 11, 2026, for this indication. Positive Phase 3 ROSELLA trial results demonstrated a 35% reduction in the risk of death, leading to high expectations for approval and market adoption. Additionally, European approval is expected by the end of 2026.
  3. Re-engagement and Potential Approval Pathway for Relacorilant in Cushing's Syndrome: While the FDA issued a Complete Response Letter (CRL) for relacorilant in Cushing's syndrome in December 2025, Corcept is actively engaged with the FDA to determine the best path forward for approval. The company remains confident in the ultimate approval of relacorilant for this indication, which, once resolved, could significantly contribute to revenue as it is expected to eventually replace Korlym and address a broader patient population.
  4. Advancement and Expansion into Additional Oncology Indications: Corcept is expanding its pipeline for relacorilant beyond platinum-resistant ovarian cancer, exploring its potential in other oncology areas. This includes ongoing studies in earlier-stage ovarian, endometrial, cervical, and pancreatic cancers. Results from the Phase 2 BELLA trial in additional ovarian and endometrial cancer settings are expected in late 2026, potentially opening new markets within the next two to three years as these trials progress toward further regulatory submissions.

AI Analysis | Feedback

Share Repurchases

  • Corcept Therapeutics announced a program in January 2024 to repurchase up to $200 million of its common stock.
  • In 2025, the company paid $245.9 million to purchase its common stock, which included amounts from its stock repurchase program, net exercise of employee stock options, and net vesting of restricted stock grants.
  • In April 2023, Corcept purchased 6.6 million shares of its common stock for $145.4 million.

Share Issuance

  • Shares outstanding were 106 million in Q4 2025, an increase of 0.7% from the prior quarter.

Capital Expenditures

  • Corcept Therapeutics invested $50,000 in capital expenditures in Q4 2025.
  • Capital expenditures for the fiscal year ending December 31, 2025, were reported as -$211,000 (implying a net inflow, or very low investment).

Better Bets vs. Corcept Therapeutics (CORT)

Peer Outperformance in Pharmaceuticals

CORT has outperformed 90% of its 59 Pharmaceuticals peers over 5Y. Pharmaceuticals ranks 7th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Pharmaceuticals constituents that CORT has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
57%
of 69 industry peers · -6.7% return
3Y
83%
of 64 industry peers · 170.4% return
5Y
90%
of 59 industry peers · 202.3% return
No Pharmaceuticals peer with a comparable growth profile has beaten CORT by more than 20pp over 5Y.
Median price return by industry across the Health Care sector, ranked by 5Y. Pharmaceuticals is CORT's own industry. Use this to see which corners of the sector have carried the returns.
Industry Names 1Y med3Y med5Y med Top 3 by 5Y
Health Care Distributors 5 16.4%84.2%198.3% CAH 522% · MCK 400% · COR 198%
Health Care Services 20 31.2%20.2%12.4% RDNT 150% · HIMS 116% · DGX 91%
Managed Health Care 8 76.8%-0.8%0.8% OSCR 155% · HQY 56% · ELV 9%
Health Care Facilities 26 17.8%19.4%-9.2% THC 258% · NHC 231% · EHC 186%
Health Care Equipment 49 -1.7%4.4%-20.2% GKOS 390% · UFPT 359% · TMDX 293%
Health Care Supplies 11 24.0%1.1%-40.5% LNTH 248% · HAE 108% · MMSI 25%
Pharmaceuticals ← 60 -18.7%1.7%-45.2% LQDA 1123% · KNSA 638% · XERS 586%
Life Sciences Tools & Services 110 -22.4%-26.1%-76.2% AXGN 400% · MEDP 187% · NTRA 156%
Health Care Technology 23 -23.5%-59.7%-83.4% VEEV -8% · DOCS -55%
Biotechnology 370 -33.7%-38.5%-83.9% ELVN 1378% · TRVI 1175% · DNTH 1141%
Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.

Latest Trefis Analyses

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

CORTXERSMDGLVKTXBIIBAMLXMedian
NameCorcept .Xeris Bi.Madrigal.Viking T.Biogen Amylyx P. 
Mkt Price70.9916.78421.6626.95250.8327.5349.26
Mkt Cap7.63.012.33.237.13.35.4
Rev LTM9643681,428010,2970666
Op Inc LTM11147-153-6491,807-176-53
FCF LTM19573-169-4631,644-130-29
FCF 3Y Avg16717-256-2541,892-127-55
CFO LTM19874-157-4632,247-130-28
CFO 3Y Avg16818-250-2542,276-126-54

Growth & Margins

CORTXERSMDGLVKTXBIIBAMLXMedian
NameCorcept .Xeris Bi.Madrigal.Viking T.Biogen Amylyx P. 
Rev Chg LTM30.0%38.4%92.8%-2.3%100.0%38.4%
Rev Chg 3Y Avg29.2%34.4%--1.1%-11.2%15.1%
Rev Chg Q64.0%44.2%50.1%-10.6%-47.1%
QoQ Delta Rev Chg LTM16.0%9.8%11.2%-2.7%-10.5%
Op Inc Chg LTM69.1%377.3%50.4%-136.0%-29.2%-11.7%19.3%
Op Inc Chg 3Y Avg20.3%169.1%12.3%-95.7%0.9%-881.3%6.6%
Op Mgn LTM11.5%12.7%-10.7%-17.6%-12.1%
Op Mgn 3Y Avg14.4%-2.6%-255.2%-22.2%-5.9%
QoQ Delta Op Mgn LTM10.7%1.8%14.4%--1.7%-6.3%
CFO/Rev LTM20.6%20.0%-11.0%-21.8%-20.3%
CFO/Rev 3Y Avg21.8%2.4%-197.9%-22.8%-12.1%
FCF/Rev LTM20.2%19.7%-11.8%-16.0%-17.8%
FCF/Rev 3Y Avg21.6%2.1%-201.4%-18.9%-10.5%

Valuation

CORTXERSMDGLVKTXBIIBAMLXMedian
NameCorcept .Xeris Bi.Madrigal.Viking T.Biogen Amylyx P. 
Mkt Cap7.63.012.33.237.13.35.4
P/S7.98.28.6-3.6-8.0
P/Op Inc68.264.9-80.8-4.920.5-18.67.8
P/EBIT68.2145.0-100.0-4.749.4-18.622.3
P/E46.6-467.4-79.3-5.1106.7-20.1-12.6
P/CFO38.241.2-78.5-6.916.5-25.24.8
Total Yield2.2%-0.2%-1.3%-19.8%0.9%-5.0%-0.7%
Dividend Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%
FCF Yield 3Y Avg2.2%-0.9%-4.0%-6.9%7.4%-19.8%-2.4%
D/E0.00.10.00.10.20.00.1
Net D/E-0.00.0-0.0-0.20.2-0.2-0.0

Returns

CORTXERSMDGLVKTXBIIBAMLXMedian
NameCorcept .Xeris Bi.Madrigal.Viking T.Biogen Amylyx P. 
1M Rtn-35.6%62.8%-6.2%7.1%7.8%4.5%5.8%
3M Rtn-39.9%89.6%-19.6%-19.2%18.0%-21.6%-19.4%
6M Rtn21.9%183.4%-17.6%-5.1%31.6%116.1%26.8%
12M Rtn-5.5%131.1%-23.8%-29.5%52.3%96.9%23.4%
3Y Rtn174.0%848.0%138.7%139.1%10.0%128.1%138.9%
1M Excs Rtn-33.1%56.8%-2.1%11.2%11.0%4.3%7.6%
3M Excs Rtn-36.5%94.9%-18.2%-21.3%17.0%-24.9%-19.7%
6M Excs Rtn21.1%182.6%-18.5%-6.0%30.8%115.2%25.9%
12M Excs Rtn-16.3%123.6%-30.4%-41.3%39.6%106.8%11.6%
3Y Excs Rtn114.8%827.9%135.8%107.4%-56.4%52.6%111.1%

Comparison Analyses

null

FDA Approved Drugs Data

Expand for More
Post-Approval Fwd Returns
FDA
App #
Brand
Name
Generic
Name
Dosage
Form
FDA
Approval
3M
Rtn
6M
Rtn
1Y
Rtn
2Y
Rtn
Total
Rtn
NDA220641  LIFYORLI (COPACKAGED)relacorilantcapsule3252026101.5%179.1%73.1%73.1%73.1%
NDA202107  KORLYMmifepristonetablet217201228.1%0.7%-39.9%2.0%2,212.5%
Collapse to Preview
Post-Approval Fwd Returns
FDA
App #
Brand
Name
Generic
Name
Dosage
Form
FDA
Approval
3M
Rtn
6M
Rtn
1Y
Rtn
2Y
Rtn
Total
Rtn
NDA220641  LIFYORLI (COPACKAGED)relacorilantcapsule3252026101.5%179.1%73.1%73.1%73.1%
NDA202107  KORLYMmifepristonetablet217201228.1%0.7%-39.9%2.0%2,212.5%

Clinical Pipeline

Drug CandidateIndicationPhase 3 TrialsEst. Primary Completion
RelacorilantPlatinum-resistant ovarian, fallopian tube, or peritoneal cancer1Mar 2025
Active Phase 3 studies led by the company. Source: ClinicalTrials.gov · Updated 8/28/2026

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Product revenue, net761675482402366
Total761675482402366


Price Behavior

Price Behavior
Market Price$70.07 
Market Cap ($ Bil)7.5 
First Trading Date04/14/2004 
Distance from 52W High-43.3% 
   50 Days200 Days
DMA Price$101.97$76.79
DMA Trenddownup
Distance from DMA-31.3%-8.8%
 3M1YR
Volatility58.4%83.4%
Downside Capture280.83271.75
Upside Capture53.35233.56
Correlation (S&P 500)48.0%31.2%
CORT Betas & Captures as of 10/31/2026

 1M2M3M6M1Y3Y
Beta3.712.461.431.571.941.37
Up Beta6.133.180.592.771.230.65
Down Beta2.133.783.631.681.131.19
Up Capture160%93%23%193%532%1294%
Bmk +ve Days12182862130427
Stock +ve Days8183071141403
Down Capture544%294%210%66%167%112%
Bmk -ve Days10253664121325
Stock -ve Days13243354109347

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with CORT
CORT-7.3%83.4%0.35-
Sector ETF (XLV)24.2%16.9%1.1018.7%
Equity (SPY)10.2%13.8%0.4530.5%
Gold (GLD)-6.3%28.8%-0.2322.7%
Commodities (DBC)31.6%21.3%1.180.2%
Real Estate (VNQ)10.0%14.2%0.426.7%
Bitcoin (BTCUSD)-31.4%43.7%-0.7515.0%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with CORT
CORT25.0%76.3%0.58-
Sector ETF (XLV)8.6%15.4%0.3620.1%
Equity (SPY)10.9%17.3%0.4623.7%
Gold (GLD)15.5%19.2%0.6511.8%
Commodities (DBC)7.1%19.6%0.254.8%
Real Estate (VNQ)0.9%19.0%-0.0616.3%
Bitcoin (BTCUSD)-0.6%51.4%0.179.8%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with CORT
CORT23.9%68.1%0.58-
Sector ETF (XLV)12.4%16.8%0.6124.7%
Equity (SPY)14.9%18.0%0.7025.9%
Gold (GLD)11.2%16.6%0.557.9%
Commodities (DBC)7.4%18.2%0.327.3%
Real Estate (VNQ)5.8%20.7%0.2416.2%
Bitcoin (BTCUSD)57.2%66.3%0.975.6%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date10302026
Short Interest: Shares Quantity9.1 Mil
Short Interest: % Change Since 101520266.3%
Average Daily Volume1.1 Mil
Days-to-Cover Short Interest8.1 days
Basic Shares Quantity106.6 Mil
Short % of Basic Shares8.6%

Earnings Returns History

Updated 11/12/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/3/2026-3.3%-10.5% 
7/29/202627.3%19.1%25.8%
4/30/202610.5%9.7%51.4%
2/24/2026-0.7%-3.3%10.9%
11/4/20257.8%11.1%21.1%
7/31/20252.7%6.4%3.8%
5/5/2025-4.3%-2.4%-5.4%
2/26/2025-5.6%-12.4%-10.6%
...
SUMMARY STATS   
# Positive121315
# Negative13129
Median Positive6.4%9.7%20.8%
Median Negative-4.3%-7.6%-7.5%
Max Positive27.3%22.5%51.4%
Max Negative-10.4%-12.7%-18.0%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/3/2026-3.3%-10.5% 
7/29/202627.3%19.1%25.8%
4/30/202610.5%9.7%51.4%
2/24/2026-0.7%-3.3%10.9%
11/4/20257.8%11.1%21.1%
7/31/20252.7%6.4%3.8%
5/5/2025-4.3%-2.4%-5.4%
2/26/2025-5.6%-12.4%-10.6%
10/30/20244.4%15.7%23.0%
7/29/2024-1.1%-5.5%-5.1%
5/1/20244.9%6.4%26.3%
2/15/2024-7.2%-8.2%-0.6%
11/1/2023-10.0%-8.3%-7.5%
8/2/202324.9%20.6%30.9%
5/3/20233.9%3.9%0.7%
2/28/2023-4.7%1.9%4.5%
11/3/2022-10.4%-9.3%-18.0%
8/3/2022-1.3%-3.4%-9.5%
5/5/2022-9.9%-12.7%0.5%
2/15/202212.8%10.6%20.8%
11/3/202110.1%22.5%14.6%
7/29/20212.4%6.7%6.1%
5/6/2021-2.8%-3.6%-1.5%
2/23/2021-0.1%-6.9%-11.2%
11/3/20202.1%3.1%31.2%
SUMMARY STATS   
# Positive121315
# Negative13129
Median Positive6.4%9.7%20.8%
Median Negative-4.3%-7.6%-7.5%
Max Positive27.3%22.5%51.4%
Max Negative-10.4%-12.7%-18.0%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202611/03/202610-Q
06/30/202607/29/202610-Q
03/31/202604/30/202610-Q
12/31/202502/24/202610-K
09/30/202511/04/202510-Q
06/30/202507/31/202510-Q
03/31/202505/05/202510-Q
12/31/202402/26/202510-K
09/30/202410/30/202410-Q
06/30/202407/29/202410-Q
03/31/202405/01/202410-Q
12/31/202302/15/202410-K
09/30/202311/01/202310-Q
06/30/202308/02/202310-Q
03/31/202305/03/202310-Q
12/31/202202/28/202310-K
Collapse to Preview
Report DateFiling DateFiling
09/30/202611/03/202610-Q
06/30/202607/29/202610-Q
03/31/202604/30/202610-Q
12/31/202502/24/202610-K
09/30/202511/04/202510-Q
06/30/202507/31/202510-Q
03/31/202505/05/202510-Q
12/31/202402/26/202510-K
09/30/202410/30/202410-Q
06/30/202407/29/202410-Q
03/31/202405/01/202410-Q
12/31/202302/15/202410-K
09/30/202311/01/202310-Q
06/30/202308/02/202310-Q
03/31/202305/03/202310-Q
12/31/202202/28/202310-K
09/30/202211/03/202210-Q
06/30/202208/04/202210-Q
03/31/202205/05/202210-Q
12/31/202102/15/202210-K
09/30/202111/03/202110-Q
06/30/202107/29/202110-Q
03/31/202105/06/202110-Q
12/31/202002/23/202110-K
09/30/202011/03/202010-Q
06/30/202008/04/202010-Q
03/31/202005/04/202010-Q
12/31/201902/24/202010-K

Recent Forward Guidance

Updated 11/4/2026

Latest: Q3 2026 Earnings Reported 11/3/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 RevenueReported1.10 Bil1.15 Bil1.20 Bil0.0% AffirmedGuidance: 1.15 Bil for 2026


Prior: Q2 2026 Earnings Reported 7/29/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 RevenueReported1.10 Bil1.15 Bil1.20 Bil15.0% RaisedGuidance: 1.00 Bil for 2026

Q1 2026 Earnings Reported 4/30/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 RevenueReported950.00 Mil1.00 Bil1.05 Bil  RaisedGuidance: 950.00 Mil for 2026

Q4 2025 Earnings Reported 2/24/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 RevenueReported900.00 Mil950.00 Mil1.00 Bil15.2% Higher NewGuidance: 825.00 Mil for 2025

Insider Activity

Updated 11/17/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Wilson, James N James N. Wilson and Pamela D. Wilson TrustSell1117202672.6710,000726,67875,904,635Form
2Swisher, Daniel N JR DirectSell1113202674.071,500  Form
3Maduck, Sean DirectSell1104202682.2513,1591,082,277817,362Form
4Maduck, Sean DirectSell1104202681.4211,841964,074809,135Form
5Vieira, Roberto WandenkolkPresident, OncologyDirectSell1104202680.898,333674,069319,198Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Wilson, James N James N. Wilson and Pamela D. Wilson TrustSell1117202672.6710,000726,67875,904,635Form
2Swisher, Daniel N JR DirectSell1113202674.071,500  Form
3Maduck, Sean DirectSell1104202682.2513,1591,082,277817,362Form
4Maduck, Sean DirectSell1104202681.4211,841964,074809,135Form
5Vieira, Roberto WandenkolkPresident, OncologyDirectSell1104202680.898,333674,069319,198Form
6Wilson, James N James N. Wilson and Pamela D. Wilson TrustSell10162026114.8110,0001,148,083121,070,262Form
7Vieira, Roberto WandenkolkPresident, OncologyDirectSell10052026116.108,333967,448458,124Form
8Lyon, Joseph DouglasSee RemarksDirectSell10052026116.139,1901,067,258659,981Form
9Maduck, SeanSee RemarksDirectSell10052026116.2824,5872,858,8841,155,553Form
10Lyon, Joseph DouglasSee RemarksDirectSell10052026115.4081093,473655,810Form
11Maduck, SeanSee RemarksDirectSell10052026115.5441347,7171,148,210Form
12Vieira, Roberto WandenkolkPresident, OncologyDirectSell9182026100.8229629,843397,836Form
13Wilson, James N James N. Wilson and Pamela D. Wilson TrustSell9162026110.6910,0001,106,940117,838,531Form
14Lyon, Joseph DouglasSee RemarksDirectSell9162026113.4910,0001,134,947644,990Form
15Vieira, Roberto WandenkolkPresident, OncologyDirectSell9032026110.7658,3336,460,766469,830Form
16Maduck, SeanSee RemarksDirectSell9032026114.4325,0002,860,7371,116,260Form
17Park, Kimberly DirectSell8282026122.5526,685  Form
18Maduck, SeanSee RemarksDirectSell8272026125.5830,9553,887,3201,225,030Form
19Mahoney, David L Held by David L. Mahoney and Winnifred C. Ellis 1998 Family TrustSell8202026118.25103,60612,251,411134,041,007Form
20Robb, Gary CharlesChief Business OfficerGary Charles Robb TTE Robb Revocable TrustSell8182026116.2610,0001,162,5724,617,271Form
21Maduck, SeanSee RemarksDirectSell8182026114.493,664419,4911,116,850Form
22Wilson, James N James N. Wilson and Pamela D. Wilson TrustSell8182026111.4310,0001,114,261119,732,095Form
23Maduck, SeanSee RemarksDirectSell8122026114.521,031118,0681,117,125Form
24Guyer, WilliamChief Development OfficerDirectSell8122026113.4316,3001,848,890452,014Form
25Maduck, SeanSee RemarksDirectSell8052026114.7020,3052,329,0751,118,942Form
26Lyon, Joseph DouglasSee RemarksDirectSell8052026114.161,540175,806627,309Form
27Mokari, AtabakChief Financial OfficerDirectSell8032026114.7180,0009,177,1091,850,335Form
28Wilson, James N James N. Wilson and Pamela D. Wilson TrustSell717202688.3010,000882,98695,763,588Form
29Mokari, AtabakChief Financial OfficerDirectSell717202687.7140,0003,508,2771,414,713Form
30Guyer, WilliamChief Development OfficerDirectSell708202693.1320,0001,862,530371,109Form
31Maduck, SeanSee RemarksDirectSell706202688.3525,0002,208,737861,849Form
32Mahoney, David L The Black Dog Private FoundationSell618202684.5320,0001,690,5062,210,083Form
33Wilson, James N James N. Wilson and Pamela D. Wilson TrustSell618202683.2010,000832,04991,071,335Form
34Mokari, AtabakChief Financial OfficerDirectSell617202681.1540,0003,245,9001,308,909Form
35Guyer, WilliamChief Development OfficerDirectSell604202670.6020,0001,412,000281,341Form
36Maduck, SeanSee RemarksDirectSell603202670.2125,0001,755,183630,251Form
37Mokari, AtabakChief Financial OfficerDirectSell603202670.0040,0002,800,0041,067,992Form
38Belanoff, Joseph KChief Executive OfficerJoseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02Sell602202669.7412,837895,252178,917,203Form
39Lyon, Joseph DouglasSee RemarksDirectSell529202665.005,000325,000404,950Form
40Maduck, SeanSee RemarksDirectSell529202665.5975,0004,918,944588,765Form
41Guyer, WilliamChief Development OfficerDirectSell507202651.8320,0001,036,600115,633Form
42Belanoff, Joseph KChief Executive OfficerJoseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02Sell505202650.1040,0002,003,860144,194,058Form
43Guyer, WilliamChief Development OfficerDirectSell408202640.9720,000819,40091,404Form
44Belanoff, Joseph KChief Executive OfficerJoseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02Sell327202650.0726,1981,311,826146,130,797Form
45Guyer, WilliamChief Development OfficerDirectSell324202636.0111,767423,73080,338Form
46Baker, G Leonard JRDirectBuy319202633.14100,0003,313,80937,997,158Form
47Guyer, WilliamChief Development OfficerDirectSell306202635.998,233296,34680,305Form
48Guyer, WilliamChief Development OfficerDirectSell205202640.8720,000817,33450,470Form
49Guyer, WilliamChief Development OfficerDirectSell1203202580.0820,0001,601,52698,894Form
50Maduck, SeanSee RemarksDirectSell1203202579.5220,0001,590,490628,562Form
51Lyon, Joseph DouglasSee RemarksDirectSell1203202579.535,000397,632817,292Form
52Belanoff, Joseph KChief Executive OfficerJoseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02Sell1203202579.7740,0003,190,796215,488,015Form
53Guyer, WilliamChief Development OfficerDirectSell1126202580.904,500364,07063,672Form
54Guyer, WilliamChief Development OfficerDirectSell1107202575.3620,0001,507,122398,408Form
55Belanoff, Joseph KChief Executive OfficerJoseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02Sell1105202574.7728,7822,152,105204,979,399Form
56Lyon, Joseph DouglasSee RemarksDirectSell1105202573.655,000368,244756,890Form
57Belanoff, Joseph KChief Executive OfficerJoseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02Sell1105202574.0811,218831,014205,208,982Form
58Maduck, SeanSee RemarksDirectSell1105202573.9920,0001,479,816584,823Form

Investor Activity (13F)

Updated Nov 18, 2026
13F holdings as of Mar 31, 2026 (Q1 2026)

Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.

Active ManagerValue% of PortfolioTotal PositionsQoQFiling
MPM Bioimpact LLC$39.7 Mil3.1%41New13F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
MPM Bioimpact LLC$39.7 Mil3.1%41New13F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Checkpoint Capital L.P.$14.0 Mil4.4%6Exited13F
Newtyn Management, LLC$7.0 Mil0.7%31Exited13F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
MPM Bioimpact LLC$39.7 Mil3.1%41New13F
Core Cache Last Updated: 11/17/2026